No significant associations were identified between CSF sαKl levels and any of the core AD biomarkers or biomarkers of neurodegeneration (NfL), neuroinflammation (GFAP) and synaptic dysfunction (Ng) in either the entire sample or within the APOE ε4 or clinical subgroups (Table 4). The gene discussed is GFAP; the disease is Alzheimer disease.